Cargando…

Efficacy and safety of edaravone for acute intracerebral haemorrhage: protocol for a systematic review and meta-analysis

INTRODUCTION: Intracerebral haemorrhage (ICH) is a life-threatening condition with no effective internal treatment options. However, edaravone is a promising therapeutic agent, although its beneficial effects are inconclusive based on previous systematic reviews and meta-analyses. While several tria...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Luda, Liang, Ning, Li, Tingting, Yang, Qinyu, Jiang, Ping, Guo, Shengnan, Zhang, Chi, Gao, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7440699/
https://www.ncbi.nlm.nih.gov/pubmed/32819956
http://dx.doi.org/10.1136/bmjopen-2020-039366
_version_ 1783573171231784960
author Feng, Luda
Liang, Ning
Li, Tingting
Yang, Qinyu
Jiang, Ping
Guo, Shengnan
Zhang, Chi
Gao, Ying
author_facet Feng, Luda
Liang, Ning
Li, Tingting
Yang, Qinyu
Jiang, Ping
Guo, Shengnan
Zhang, Chi
Gao, Ying
author_sort Feng, Luda
collection PubMed
description INTRODUCTION: Intracerebral haemorrhage (ICH) is a life-threatening condition with no effective internal treatment options. However, edaravone is a promising therapeutic agent, although its beneficial effects are inconclusive based on previous systematic reviews and meta-analyses. While several trials in the last 8 years have reported the favourable long-term functional outcomes, a few reports indicated edaravone to be associated with an increase in adverse events. METHODS AND ANALYSIS: This protocol was performed in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols. We will perform the comprehensive and manual search for published articles, ongoing trials, dissertations and grey literature. The following databases will be searched from inception to 23 April 2020: Medline, Embase, the Cochrane Central Register of Controlled Trials, China National Knowledge Infrastructure, Chinese scientific periodical database of VIP INFORMATION, Wanfang Data and SinoMed, with no language restrictions. All randomised controlled trials that (1) compared edaravone with placebo or no treatment, and (2) compared edaravone plus routine treatment or cointervention with routine treatment or cointervention for treating acute ICH will be included. Mortality and long-term dependency will be the primary outcomes. The incidence of adverse events will be assessed for safety evaluation. Two reviewers in pairs will independently carry out the article selection, data extraction and quality assessment. Assessment of the risk of bias and data synthesis will be performed using software Review Manager V.5.3. Finally, we will use the Grading of Recommendations Assessment, Development and Evaluation approach to evaluate the quality of the overall evidence. ETHICS AND DISSEMINATION: There are no ethical considerations associated with this updated systematic review and meta-analysis. The findings will be disseminated in peer-reviewed journals or conference presentations. PROSPERO REGISTRATION NUMBER: CRD42019147801.
format Online
Article
Text
id pubmed-7440699
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-74406992020-08-28 Efficacy and safety of edaravone for acute intracerebral haemorrhage: protocol for a systematic review and meta-analysis Feng, Luda Liang, Ning Li, Tingting Yang, Qinyu Jiang, Ping Guo, Shengnan Zhang, Chi Gao, Ying BMJ Open Neurology INTRODUCTION: Intracerebral haemorrhage (ICH) is a life-threatening condition with no effective internal treatment options. However, edaravone is a promising therapeutic agent, although its beneficial effects are inconclusive based on previous systematic reviews and meta-analyses. While several trials in the last 8 years have reported the favourable long-term functional outcomes, a few reports indicated edaravone to be associated with an increase in adverse events. METHODS AND ANALYSIS: This protocol was performed in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols. We will perform the comprehensive and manual search for published articles, ongoing trials, dissertations and grey literature. The following databases will be searched from inception to 23 April 2020: Medline, Embase, the Cochrane Central Register of Controlled Trials, China National Knowledge Infrastructure, Chinese scientific periodical database of VIP INFORMATION, Wanfang Data and SinoMed, with no language restrictions. All randomised controlled trials that (1) compared edaravone with placebo or no treatment, and (2) compared edaravone plus routine treatment or cointervention with routine treatment or cointervention for treating acute ICH will be included. Mortality and long-term dependency will be the primary outcomes. The incidence of adverse events will be assessed for safety evaluation. Two reviewers in pairs will independently carry out the article selection, data extraction and quality assessment. Assessment of the risk of bias and data synthesis will be performed using software Review Manager V.5.3. Finally, we will use the Grading of Recommendations Assessment, Development and Evaluation approach to evaluate the quality of the overall evidence. ETHICS AND DISSEMINATION: There are no ethical considerations associated with this updated systematic review and meta-analysis. The findings will be disseminated in peer-reviewed journals or conference presentations. PROSPERO REGISTRATION NUMBER: CRD42019147801. BMJ Publishing Group 2020-08-20 /pmc/articles/PMC7440699/ /pubmed/32819956 http://dx.doi.org/10.1136/bmjopen-2020-039366 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Neurology
Feng, Luda
Liang, Ning
Li, Tingting
Yang, Qinyu
Jiang, Ping
Guo, Shengnan
Zhang, Chi
Gao, Ying
Efficacy and safety of edaravone for acute intracerebral haemorrhage: protocol for a systematic review and meta-analysis
title Efficacy and safety of edaravone for acute intracerebral haemorrhage: protocol for a systematic review and meta-analysis
title_full Efficacy and safety of edaravone for acute intracerebral haemorrhage: protocol for a systematic review and meta-analysis
title_fullStr Efficacy and safety of edaravone for acute intracerebral haemorrhage: protocol for a systematic review and meta-analysis
title_full_unstemmed Efficacy and safety of edaravone for acute intracerebral haemorrhage: protocol for a systematic review and meta-analysis
title_short Efficacy and safety of edaravone for acute intracerebral haemorrhage: protocol for a systematic review and meta-analysis
title_sort efficacy and safety of edaravone for acute intracerebral haemorrhage: protocol for a systematic review and meta-analysis
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7440699/
https://www.ncbi.nlm.nih.gov/pubmed/32819956
http://dx.doi.org/10.1136/bmjopen-2020-039366
work_keys_str_mv AT fengluda efficacyandsafetyofedaravoneforacuteintracerebralhaemorrhageprotocolforasystematicreviewandmetaanalysis
AT liangning efficacyandsafetyofedaravoneforacuteintracerebralhaemorrhageprotocolforasystematicreviewandmetaanalysis
AT litingting efficacyandsafetyofedaravoneforacuteintracerebralhaemorrhageprotocolforasystematicreviewandmetaanalysis
AT yangqinyu efficacyandsafetyofedaravoneforacuteintracerebralhaemorrhageprotocolforasystematicreviewandmetaanalysis
AT jiangping efficacyandsafetyofedaravoneforacuteintracerebralhaemorrhageprotocolforasystematicreviewandmetaanalysis
AT guoshengnan efficacyandsafetyofedaravoneforacuteintracerebralhaemorrhageprotocolforasystematicreviewandmetaanalysis
AT zhangchi efficacyandsafetyofedaravoneforacuteintracerebralhaemorrhageprotocolforasystematicreviewandmetaanalysis
AT gaoying efficacyandsafetyofedaravoneforacuteintracerebralhaemorrhageprotocolforasystematicreviewandmetaanalysis